Distinct clinical and metabolic deficits in PCA and AD are not related to amyloid distribution

HealthPartner Specialty Center, Center for Dementia and Alzheimer's Care, 401 Phalen Boulevard, Mail Stop: 41104C, St. Paul, MN 55130, USA.
Neurology (Impact Factor: 8.3). 05/2011; 76(21):1789-96. DOI: 10.1212/WNL.0b013e31821cccad
Source: PubMed

ABSTRACT Patients with posterior cortical atrophy (PCA) often have Alzheimer disease (AD) at autopsy, yet are cognitively and anatomically distinct from patients with clinical AD. We sought to compare the distribution of β-amyloid and glucose metabolism in PCA and AD in vivo using Pittsburgh compound B (PiB) and FDG-PET.
Patients with PCA (n = 12, age 57.5 ± 7.4, Mini-Mental State Examination [MMSE] 22.2 ± 5.1), AD (n = 14, age 58.8 ± 9.6, MMSE 23.8 ± 6.7), and cognitively normal controls (NC, n = 30, age 73.6 ± 6.4) underwent PiB and FDG-PET. Group differences in PiB distribution volume ratios (DVR, cerebellar reference) and FDG uptake (pons-averaged) were assessed on a voxel-wise basis and by comparing binding in regions of interest (ROIs).
Compared to NC, both patients with AD and patients with PCA showed diffuse PiB uptake throughout frontal, temporoparietal, and occipital cortex (p < 0.0001). There were no regional differences in PiB binding between PCA and AD even after correcting for atrophy. FDG patterns in PCA and AD were distinct: while both groups showed hypometabolism compared to NC in temporoparietal cortex and precuneus/posterior cingulate, patients with PCA further showed hypometabolism in inferior occipitotemporal cortex compared to both NC and patients with AD (p < 0.05). Patients with AD did not show areas of relative hypometabolism compared to PCA.
Fibrillar amyloid deposition in PCA is diffuse and similar to AD, while glucose hypometabolism extends more posteriorly into occipital cortex. Further studies are needed to determine the mechanisms of selective network degeneration in focal variants of AD.

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Analysis of neural data with multiple modes and high density has recently become a trend with the advances in neuroscience research and practices. There exists a pressing need for an approach to accurately and uniquely capture the features without loss or destruction of the interactions amongst the modes (typically) of space, time, and frequency. Moreover, the approach must be able to quickly analyze the neural data of exponentially growing scales and sizes, in tens or even hundreds of channels, so that timely conclusions and decisions may be made. A salient approach to multi-way data analysis is the parallel factor analysis (PARAFAC) that manifests its effectiveness in the decomposition of the electroencephalography (EEG). However, the conventional PARAFAC is only suited for offline data analysis due to the high complexity, which computes to be O(n2) with the increasing data size. In this study, a large-scale PARAFAC method has been developed, which is supported by general-purpose computing on the graphics processing unit (GPGPU). Comparing to the PARAFAC running on conventional CPU-based platform, the new approach dramatically excels by >360 times in run-time performance, and effectively scales by >400 times in all dimensions. Moreover, the proposed approach forms the basis of a model for the analysis of electrocochleography (ECoG) recordings obtained from epilepsy patients, which proves to be effective in the epilepsy state detection. The time evolutions of the proposed model are well correlated with the clinical observations. Moreover, the frequency signature is stable and high in the ictal phase. Furthermore, the spatial signature explicitly identifies the propagation of neural activities among various brain regions. The model supports real-time analysis of ECoG in > 1;000 channels on an inexpensive and available cyber-infrastructure.
  • [Show abstract] [Hide abstract]
    ABSTRACT: Alzheimer's disease (AD) has a complex and progressive neurodegenerative phenotype, with hypometabolism and impaired mitochondrial bioenergetics among the earliest pathogenic events. Bioenergetic deficits are well documented in preclinical models of mammalian aging and AD, emerge early in the prodromal phase of AD, and in those at risk for AD. This review discusses the importance of early therapeutic intervention during the prodromal stage that precedes irreversible degeneration in AD. Mechanisms of action for current mitochondrial and bioenergetic therapeutics for AD broadly fall into the following categories: 1) glucose metabolism and substrate supply; 2) mitochondrial enhancers to potentiate energy production; 3) antioxidants to scavenge reactive oxygen species and reduce oxidative damage; 4) candidates that target apoptotic and mitophagy pathways to either remove damaged mitochondria or prevent neuronal death. Thus far, mitochondrial therapeutic strategies have shown promise at the preclinical stage but have had little-to-no success in clinical trials. Lessons learned from preclinical and clinical therapeutic studies are discussed. Understanding the bioenergetic adaptations that occur during aging and AD led us to focus on a systems biology approach that targets the bioenergetic system rather than a single component of this system. Bioenergetic system-level therapeutics personalized to bioenergetic phenotype would target bioenergetic deficits across the prodromal and clinical stages to prevent and delay progression of AD.
    Journal of the American Society for Experimental NeuroTherapeutics 12/2014; 12(1). DOI:10.1007/s13311-014-0324-8 · 3.88 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Posterior cortical atrophy (PCA) is characterized by progressive higher-order visuoperceptual dysfunction and praxis declines. This syndrome is related to a number of underlying diseases, including, in most cases, Alzheimer's disease (AD). The aim of this study was to compare the amyloid load with (18)F-AV45 positron emission tomography (PET) between PCA and AD subjects. We performed (18)F-AV45 PET, cerebrospinal fluid (CSF) biomarker analysis and a neuropsychological assessment in 11 PCA patients and 12 AD patients. The global and regional (18)F-AV45 uptake was similar in the PCA and AD groups. No significant correlation was observed between global (18)F-AV45 uptake and CSF biomarkers or between regional (18)F-AV45 uptake and cognitive and affective symptoms. This (18)F-AV45 PET amyloid imaging study showed no specific regional pattern of cortical (18)F-AV45 binding in PCA patients. These results confirm that a distinct clinical phenotype in amnestic AD and PCA is not related to amyloid distribution.


Available from